Paroxetine updated on 07-01-2025

Craniosynostosis

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7470
R22277		 Anderson, 2020 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.61 [0.80;3.23] -/-   0/- - -
ref
S7434
R21900		 Bérard, 2017 Craniosynostosis 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 1.53 [0.72;3.25] -/1,132   -/14,847 - 1,132
ref
S7350
R21484		 Wemakor, 2015 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 2.06 [0.28;15.24] C 1/28   306/17,362 307 28
ref
S6243
R16515		 Malm, 2011 Craniocynostosis 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 2.16 [0.30;15.64] -/968   -/628,607 - 968
ref
S6160
R16169		 Louik, 2007 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.70 [0.20;14.40] 1/31   114/5,944 115 31
ref
Total 5 studies 1.63 [1.02;2.61] 422 2,159
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.61[0.80; 3.23]--45%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Bérard, 2017Bérard, 2017 1.53[0.72; 3.25]-1,13239%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Wemakor, 2015Wemakor, 2015 2.06[0.28; 15.24]307286%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Malm, 2011Malm, 2011 2.16[0.30; 15.64]-9686%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Louik, 2007Louik, 2007 1.70[0.20; 14.40]115315%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (5 studies) I2 = 0% 1.63[1.02; 2.61]4222,1590.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.60[0.79; 3.23]-2,1000%NABérard, 2017 Malm, 2011 2 case control studiescase control studies 1.66[0.88; 3.11]422590%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.70[0.93; 3.10]4221,0270%NAAnderson, 2020 Wemakor, 2015 Malm, 2011 Louik, 2007 4 unexposed, sickunexposed, sick 1.53[0.72; 3.25]-1,132 -NABérard, 2017 1 Tags Adjustment   - No  - No 2.06[0.28; 15.24]30728 -NAWemakor, 2015 1   - Yes  - Yes 1.61[0.99; 2.61]1152,1310%NAAnderson, 2020 Bérard, 2017 Malm, 2011 Louik, 2007 4 Monotherapy   - no or not specified  - no or not specified 2.16[0.30; 15.60]-968 -NAMalm, 2011 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.60[0.97; 2.63]3071,1600%NAAnderson, 2020 Bérard, 2017 Wemakor, 2015 3   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.70[0.20; 14.42]11531 -NALouik, 2007 1 Unexposed sick   - intermediate history of illness/tre ...  - intermediate history of illness/treatment (3-12 months before pregnancy) 1.53[0.72; 3.25]-1,132 -NABérard, 2017 1 All studiesAll studies 1.63[1.02; 2.61]4222,1590%NAAnderson, 2020 Bérard, 2017 Wemakor, 2015 Malm, 2011 Louik, 2007 50.55.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.63.11.3090.000Anderson, 2020Bérard, 2017Wemakor, 2015Malm, 2011Louik, 2007

Asymetry test p-value = 0.0790 (by Egger's regression)

slope=0.3338 (0.0668); intercept=0.3268 (0.1248); t=2.6193; p=0.0790

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.70[0.93; 3.10]4221,0270%NAAnderson, 2020 Wemakor, 2015 Malm, 2011 Louik, 2007 4 unexposed, sick controlsunexposed, sick controls 1.53[0.72; 3.25]-1,132 -NABérard, 2017 10.510.01.0